secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001650664-23-000034
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reports EDIT-301 (reni-cel) data: all 11 SCD patients free of vaso-occlusive events
--------------------------------------------------------------------------------

- All 11 SCD patients in RUBY trial free of vaso-occlusive events post reni-cel; 6 with >=5 months follow-up achieved normal Hb and >40% fetal Hb.
- 6 TDT patients in EdiTHAL trial showed early robust total hemoglobin rise above 9 g/dL transfusion independence threshold.
- Reni-cel well-tolerated in all 17 patients; safety profile consistent with myeloablative conditioning; no SAEs related to reni-cel reported.
- Data presented at ASH and company webinar; additional dosing and further updates expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000034/0001650664-23-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000034/edit-20231211.htm
  HTML page:      https://secwatch.observer/filing/0001650664-23-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer